Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2002

View Archived Issues

David Pharmaceuticals changes name, advances cognitive compounds

Leptin gene therapy in rats fed a high-fat diet

The novel spin trap agent NXY-059 improves safety profile of tPA

Sevelamer prevents progressive coronary and aortic calcification in hemodialysis patients

Pharmacia submits NDA for eplerenone in Japan

NEO-339 improves attention deficits, learning and memory in animals

Schering AG acquires MAP Medical Technologies

ETC-642 phase I results consistent with preclinical studies

Millennium discontinues oral MLN-977 program

NitroMed presents novel CINOD that compares favorably with naproxen

Retinal neuroprotective effects demonstrated for (-)-MR-22 and flunarizine in rat model

Effects of S-23478 characterized in rat models, discussed at scientific meetings

PRO-542 active in all primary target cells, particularly effective in treatment-experienced patients

Antinociceptive effects of a selective NMDA NR2B subunit antagonist

SR-140333 effective in rat model of cutaneous inflammatory pain

Janssen presents novel MTP inhibitors and their use in lipoprotein disorders

New vitamin D analogues for skin disorders emerge from Roche R&D

Celltech identifies new inhibitors of LFA-1/ICAM-1 interaction

Selective alpha4 integrin inhibitors in early development at Celltech R&D

Fumagillin derivatives and their use in angiogenesis disorders

New antifungal compound isolated from Pseudallescheria cultures at Yamanouchi

Researchers at GSK describe new 5-HT6 ligands for depression, anxiety, etc.

FDA grants priority review for Pegasys combination treatment

Amgen completes acquisition of Immunex

Telik exercises option to develop compounds from Arizona Cancer Center collaboration

GTC Biotherapeutics completes rhATIII study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...